$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
治疗乳腺癌的PARP抑制剂-奥拉帕尼
2025-10-19 11:44:20
Check Details
乳腺癌患者使用奥拉帕尼的禁忌和注意事项
2025-10-19 11:44:20
Check Details
奥拉帕尼在治疗乳腺癌这方面的效果显著
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗HER2阴性转移性乳腺癌的安全性和有效性
2025-10-19 11:44:20
Check Details
奥拉帕尼可有效改善转移性乳腺癌患者的生存期
2025-10-19 11:44:20
Check Details
PARP抑制剂奥拉帕尼可用于治疗乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼2021年在国内进入医保后的价格
2025-10-19 11:44:20
Check Details
奥拉帕尼用于治疗生殖系BRCA基因突变、HER2阴性的转移性乳腺癌
2025-10-19 11:44:20
Check Details
用瑞宁得来治疗乳腺癌有什么优势?
2025-10-19 11:44:20
Check Details
来那替尼2021年在中国纳入国家医保了吗?
2025-10-19 11:44:20
Check Details
乳腺癌术后可以服用瑞宁得进行治疗吗?
2025-10-19 11:44:20
Check Details
来那替尼是HER2药物中靶点最为广泛的一类药物
2025-10-19 11:44:20
Check Details
1
2
...
1993
1994
1995
1996
1997
1998
1999
...
4159
4160
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
2
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
3
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
4
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
5
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
6
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
7
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
8
Lapatinib: Proper Administration Guide and Key Precautions
9
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
10
Cemiplimab Storage and Handling Guide
11
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
12
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring